复宏汉霖(02696)盘中涨超5%,截至发稿,股价上涨3.42%,现报17.56港元,成交额413.68万港元。
消息面上,复宏汉霖公告,公司自主研发的Perjeta (帕妥珠单抗)生物类似药候选药HLX11的生物制品许可申请(BLA)获美国食品药品管理局(FDA)受理。据悉,HLX11是公司自主研发的帕妥珠单抗生物类似药,拟用于HER2阳性早期乳腺癌的新辅助/辅助治疗、HER2阳性转移性乳腺癌的治疗及与原研药药品标签相符的其他适应症。
责任编辑:卢昱君
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.